Pancreatic Cancer Research

ResearcherNanjing University of Chinese MedicineActive in the last 2 years

Baorui Liu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-2539-7732; OpenAlex author ID A5004716187. Sources: OpenAlex.

Their work

Papers
14 (first author 0, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
26
Papers, trials and grants by year

2021: 1 paper · 2022: 7 papers · 2023: 2 papers · 2024: 2 papers · 2025: 1 paper · 2026: 1 paper

Papers 14

  1. Radiotherapy-synergized in situ hydrogel vaccine with engineered Lactococcus lactis FOLactis potentiates anti-tumor immunity in pancreatic cancer. Co-author DOI 10.3389/fimmu.2026.1789212↗
  2. Construction of feature selection and efficacy prediction model for transformation therapy of locally advanced pancreatic cancer based on CT, 18F-FDG PET/CT, D… Co-author DOI 10.1186/s12935-025-03639-8↗
  3. First-line penpulimab (an anti-PD1 antibody) and anlotinib (an angiogenesis inhibitor) with nab-paclitaxel/gemcitabine (PAAG) in metastatic pancreatic cancer: … Co-author DOI 10.1038/s41392-024-01857-6↗
  4. Efficacy and safety of second-line therapy by S-1 combined with sintilimab and anlotinib in pancreatic cancer patients with liver metastasis: a single-arm, pha… Co-author DOI 10.3389/fimmu.2024.1210859↗
  5. Biomarkers for predicting tumor response to PD-1 inhibitors in patients with advanced pancreatic cancer. Co-author DOI 10.1080/21645515.2023.2178791↗
  6. Making "cold" tumors "hot"- radiotherapy remodels the tumor immune microenvironment of pancreatic cancer to benefit from immunotherapy: a case report. Co-author DOI 10.3389/fimmu.2023.1277810↗
  7. Efficacy and safety of immune checkpoint inhibitors in advanced pancreatic cancer: A real world study in Chinese cohort. Co-author DOI 10.1080/21645515.2022.2143154↗
  8. Advanced Pancreatic Cancer Patient Benefit From Personalized Neoantigen Nanovaccine Based Immunotherapy: A Case Report. Last author DOI 10.3389/fimmu.2022.799026↗
  9. Therapeutic effect and safety of individualized chemotherapy combined with sequential immunotherapy based on BRCA1 mRNA expression level in unresectable pancre… Last author DOI 10.3389/fonc.2022.1015232↗
  10. Use of Nab-Paclitaxel Plus Gemcitabine Followed by Hypofractionated Tomotherapy With Simultaneous Integrated Boost in Patients With Locally Advanced Pancreatic… Co-author DOI 10.3389/fonc.2022.782730↗
  11. Molecular Landscape and Prognostic Biomarker Analysis of Advanced Pancreatic Cancer and Predictors of Treatment Efficacy of AG Chemotherapy. Last author DOI 10.3389/fonc.2022.844527↗
  12. Study protocol for a prospective, open-label, single-arm, phase II study on the combination of tislelizumab, nab-paclitaxel, gemcitabine, and concurrent radiot… Co-author DOI 10.3389/fonc.2022.879661↗
  13. Case Report: Pathologic Complete Response to Induction Therapy in a Patient With Potentially Resectable Pancreatic Cancer. Co-author DOI 10.3389/fonc.2022.898119↗
  14. AGIG Chemo-Immunotherapy in Patients With Advanced Pancreatic Cancer: A Single-Arm, Single-Center, Phase 2 Study. Co-author DOI 10.3389/fonc.2021.693386↗

Closest collaborators

The 25 strongest of 26 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Juan Du · 9 shared papers, 2021–2024 · strength 1.42
  2. Changchang Lu · 9 shared papers, 2021–2024 · strength 1.34
  3. Xin Qiu · 9 shared papers, 2021–2024 · strength 1.34
  4. Fan Tong · 5 shared papers, 2022–2024 · strength 0.86
  5. Huizi Sha · 5 shared papers, 2021–2024 · strength 0.84
  6. Juan Du · 4 shared papers, 2022–2025 · strength 0.68
  7. Qiao-Li Wang · 3 shared papers, 2022–2024 · strength 0.52
  8. Yudong Qiu · 4 shared papers, 2022 · strength 0.52
  9. Liang Qi · 2 shared papers, 2023–2025 · strength 0.43
  10. Lei Wang · 3 shared papers, 2022 · strength 0.37
  11. Qi Li · 3 shared papers, 2022 · strength 0.37
  12. Zhan Shi · 2 shared papers, 2022–2023 · strength 0.34
  13. Xiang Li · 1 shared paper, 2025 · strength 0.27
  14. J M Chen · 1 shared paper, 2026 · strength 0.26
  15. Juan Du · 1 shared paper, 2026 · strength 0.26
  16. Linxi Zhu · 2 shared papers, 2022 · strength 0.25
  17. Jun Chen · 2 shared papers, 2022 · strength 0.25
  18. Juan Liu · 1 shared paper, 2022 · strength 0.16
  19. Jie Shao · 1 shared paper, 2022 · strength 0.14
  20. Xiaoling Gong · 1 shared paper, 2022 · strength 0.14
  21. Yujie Zhou · 1 shared paper, 2022 · strength 0.14
  22. Wangshu Dai · 1 shared paper, 2021 · strength 0.14
  23. Jian He · 1 shared paper, 2022 · strength 0.13
  24. Xin Zhang · 1 shared paper, 2022 · strength 0.13
  25. Ju Dong Yang · 1 shared paper, 2022 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.